MinuteCE®
A robust collection of short-form, digestible CE activities that are made to fit into any schedule. With MinuteCE, you’re in control of the content you want, when you want it. To start microlearning, follow these simple steps:
Step 1: Select the episodes & 1-minute challenges you'd like to consume
Step 2: Bank time as you blaze your way through the program
Step 3: Claim credit once available as shown in the Progress Bar
Step 4: Track the status of credits claimed in your profile
Why choose microlearning?
- Bite-sized episodes
- The most relevant content
- Improved retention
To experience MinuteCE for yourself, select one of the episodes below to start learning!
Episodes 346-360 of 403
Accurate Staging and Determining Resectability in NSCLC
MinuteCE®Accurate Staging and Determining Resectability in NSCLC
Consolidative Immunotherapy in Unresectable Stage III NSCLC With Oncogenic Drivers
MinuteCE®Consolidative Immunotherapy in Unresectable Stage III NSCLC With Oncogenic Drivers
Differentiating and Managing Pneumonitis in Unresectable Stage III NSCLC: Case Discussion
MinuteCE®Differentiating and Managing Pneumonitis in Unresectable Stage III NSCLC: Case Discussion
Consolidation Immunotherapy After Concurrent CRT: What Do Real-World Data Show?
MinuteCE®Consolidation Immunotherapy After Concurrent CRT: What Do Real-World Data Show?
Unresectable Stage III NSCLC: Highlights From the Oncology Meeting in Chicago 2024
MinuteCE®Unresectable Stage III NSCLC: Highlights From the Oncology Meeting in Chicago 2024
Chemoradiotherapy Toxicities: How Do They Impact Starting Immunotherapy?
MinuteCE®Chemoradiotherapy Toxicities: How Do They Impact Starting Immunotherapy?
Consolidative Immunotherapy Following sCRT vs RT Only in Stage III NSCLC
MinuteCE®Consolidative Immunotherapy Following sCRT vs RT Only in Stage III NSCLC
Optimizing Consolidative Immunotherapy in Unresectable Stage III NSCLC: Case Discussion
MinuteCE®Optimizing Consolidative Immunotherapy in Unresectable Stage III NSCLC: Case Discussion
Immunotherapy Approaches in Unresectable Stage III NSCLC: What’s on the Horizon?
MinuteCE®Immunotherapy Approaches in Unresectable Stage III NSCLC: What’s on the Horizon?
Resolving Practice Barriers to Consolidative Immunotherapy in Stage III NSCLC
MinuteCE®Resolving Practice Barriers to Consolidative Immunotherapy in Stage III NSCLC
Initial BTK Inhibitor-Based Treatment Selection in a Treatment-Naive, Symptomatic, Unfit Older Patient With Comorbidities and High-Risk Cytogenetics
MinuteCE®Initial BTK Inhibitor-Based Treatment Selection in a Treatment-Naive, Symptomatic, Unfit Older Patient With Comorbidities and High-Risk Cytogenetics
Safety and Tolerability of Changing Covalent BTK Inhibitor Treatment in a Patient Intolerant to Ibrutinib or Acalabrutinib
MinuteCE®Safety and Tolerability of Changing Covalent BTK Inhibitor Treatment in a Patient Intolerant to Ibrutinib or Acalabrutinib
Selection of BTK Inhibitor Following Frontline Chemoimmunotherapy in Older Patients With Comorbidities
MinuteCE®Selection of BTK Inhibitor Following Frontline Chemoimmunotherapy in Older Patients With Comorbidities
